List of Excipients in Branded Drug LYRICA CR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	LYRICA CR	pregabalin	58151-245	CARBOMER HOMOPOLYMER TYPE
Viatris Specialty LLC	LYRICA CR	pregabalin	58151-245	CROSPOVIDONE
Viatris Specialty LLC	LYRICA CR	pregabalin	58151-245	KOLLIDON SR
Viatris Specialty LLC	LYRICA CR	pregabalin	58151-245	MAGNESIUM STEARATE
Viatris Specialty LLC	LYRICA CR	pregabalin	58151-245	POLYETHYLENE GLYCOL
Viatris Specialty LLC	LYRICA CR	pregabalin	58151-245	POLYVINYL ALCOHOL

LYRICA CR Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

LYRICA CR is Pfizer’s once-daily extended-release pregabalin tablet. Its commercial value depends on controlled drug release, administration after the evening meal, and a formulation architecture that differs materially from immediate-release pregabalin. The main excipient opportunity is an extended-release hydrophilic matrix based on hypromellose, supported by compression, flow, lubrication, and film-coating systems. Generic and reformulation opportunities exist, but the principal barriers are formulation performance, food-effect control, dose-strength matching, regulatory evidence, and potential patent claims directed to extended-release delivery.

What is LYRICA CR and how does its formulation differ from LYRICA?

LYRICA CR contains pregabalin in an extended-release tablet designed for once-daily administration. The approved strengths are 82.5 mg, 165 mg, and 330 mg. Patients take the tablet after an evening meal and swallow it whole. The product is not interchangeable with immediate-release LYRICA on a milligram-for-milligram basis because the release profile and pharmacokinetic exposure differ (U.S. Food and Drug Administration [FDA], 2017).

Attribute	LYRICA immediate release	LYRICA CR
Active ingredient	Pregabalin	Pregabalin
Administration	Usually two or three times daily	Once daily
Dosage form	Immediate-release capsule or oral solution	Extended-release tablet
Approved strengths	Multiple capsule strengths and oral solution	82.5 mg, 165 mg, 330 mg
Food instruction	May be taken with or without food	Taken after an evening meal
Release technology	Immediate release	Matrix-based extended release
Generic substitution	Conventional pregabalin generics	Requires an extended-release product with comparable performance

The commercial distinction is important. A conventional pregabalin capsule does not automatically compete as an equivalent substitute for LYRICA CR. A company seeking to compete directly must reproduce the extended-release profile, strength architecture, food-use instructions, and safety labeling.

What excipients are used in LYRICA CR?

The LYRICA CR label identifies hypromellose, povidone, talc, colloidal silicon dioxide, magnesium stearate, and tablet-coating components among the inactive ingredients. The exact excipient function depends on whether the material is used in the tablet core or film coating (FDA, 2017).

Excipient class	Likely formulation function	Commercial relevance
Hypromellose	Hydrophilic matrix former and release-rate controller	Core controlled-release technology
Povidone	Binder and granulation aid	Supports tablet strength and content uniformity
Colloidal silicon dioxide	Glidant and flow modifier	Important for high-dose tablet manufacture
Magnesium stearate	Lubricant	Controls ejection force and tooling performance
Talc	Processing aid and coating component	Supports film-coating and anti-adherence performance
Film-coating polymers and pigments	Protection, identification, swallowability, and appearance	Provides product differentiation and handling benefits

Hypromellose is the central excipient opportunity. In a hydrophilic matrix tablet, the polymer hydrates on contact with gastrointestinal fluid and forms a gel layer. Drug release is governed by polymer hydration, gel erosion, diffusion, tablet geometry, drug loading, compression force, and excipient particle-size distribution.

The formulation does not create a simple “buy-and-blend” opportunity. Changing hypromellose viscosity grade, substitution pattern, particle size, or supplier can alter dissolution and food-effect behavior. A generic manufacturer would need tight control of polymer specifications and supplier changes.

How does the LYRICA CR release mechanism create excipient opportunities?

The most direct opportunity is supply of high-performance hypromellose grades for controlled-release tablets. Suppliers can compete on:

• Hydration rate and gel strength
• Viscosity consistency
• Particle-size distribution
• Low-peroxide and low-impurity profiles
• Batch-to-batch dissolution performance
• Compatibility with direct compression or wet granulation
• Regulatory support for multiple global markets

High-dose pregabalin creates a formulation challenge. The 330 mg strength requires substantial drug loading while maintaining acceptable tablet size, mechanical strength, and release control. The excipient system must preserve uniformity without making the dosage form too large for routine swallowing.

Povidone and silica create secondary opportunities. A supplier that can improve granulation, powder flow, or content uniformity may reduce manufacturing variability. Magnesium stearate remains a standard lubricant, but over-lubrication can reduce tablet hardness and alter dissolution. Controlled lubrication time and mixing intensity are therefore part of the critical process strategy.

Film-coating suppliers can compete through lower coating weight, faster processing, color consistency, reduced tack, and improved moisture protection. Those advantages are commercially relevant when a product requires several strengths with similar appearance and reliable identification.

What formulation patents protect LYRICA CR?

The relevant intellectual-property analysis is different from the original LYRICA composition-of-matter estate. Pregabalin’s basic compound protection has expired in the United States, while extended-release patents and formulation claims can create separate barriers for LYRICA CR-type products.

Potentially relevant claim categories include:

1. Extended-release pregabalin tablets.
2. Hydrophilic polymer matrix systems.
3. Specific dose strengths and release profiles.
4. Once-daily administration.
5. Food-dependent dosing conditions.
6. Methods of treating fibromyalgia, neuropathic pain, or seizure disorders using extended-release pregabalin.
7. Manufacturing processes that produce a defined dissolution profile.

The FDA Orange Book should control the active patent and exclusivity assessment for the U.S. product. Patent-family analysis should also review United States Patent and Trademark Office records, international counterparts, terminal disclaimers, PTA calculations, and litigation settlements. Orange Book listings can differ from broader patent-family searches because not every formulation or method-of-use patent is listed for every product (FDA, n.d.-a).

A formulation supplier should assume that excipient selection alone will not avoid infringement if the claims are drafted around the finished dosage form, polymer matrix, dissolution profile, or method of use. A freedom-to-operate review should map each proposed formulation against claim limitations rather than rely on differences in excipient brand or grade.

When did LYRICA CR lose exclusivity?

LYRICA CR received FDA approval in 2017. Its commercial exclusivity analysis must separate regulatory exclusivity from patent protection:

Exclusivity category	LYRICA CR implication
New drug exclusivity	The NDA received approval for an extended-release pregabalin product
Orphan-drug exclusivity	Not the principal basis of the product’s U.S. protection
Composition-of-matter patent	Pregabalin’s original compound protection is separate from CR protection
Formulation patents	May protect the extended-release dosage form after compound expiry
Method-of-use patents	May affect particular indications or labeling
Orange Book-listed patents	Determine ANDA Paragraph IV timing and potential litigation

A generic applicant can submit an ANDA with Paragraph IV certifications against listed patents. FDA approval timing depends on patent expiration, litigation, pediatric exclusivity, 30-month stays, settlement terms, and any applicable first-filer rights under the Hatch-Waxman Act (FDA, n.d.-b).

The commercial risk is therefore not defined by the expiration of the original pregabalin patent alone. A company can face later entry barriers if a listed extended-release patent remains enforceable or if its product label would induce infringement of a method-of-use claim.

What FDA regulatory pathway applies to a generic LYRICA CR product?

A direct generic competitor would generally pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, including the extended-release performance relevant to the approved label.

Key development requirements include:

• Matching the reference strength set or an approved subset.
• Demonstrating comparable pharmacokinetic exposure.
• Characterizing fed and fasted performance where required.
• Producing comparable in vitro dissolution profiles.
• Establishing dose proportionality or clinically relevant exposure across strengths.
• Controlling tablet size, coating, and mechanical integrity.
• Supporting manufacturing-process validation.

A 505(b)(2) application may be commercially relevant for a modified pregabalin product that does not fit the ANDA pathway. It could support a different release profile, dosage strength, dosing schedule, or delivery system, but it would typically face greater clinical and regulatory requirements than a standard ANDA.

What Paragraph IV challenges and litigation affect LYRICA CR?

Paragraph IV risk depends on the current Orange Book listing and the applicant’s certification strategy. The main litigation issues are likely to involve:

• Whether the accused product falls within the extended-release formulation claims.
• Whether the proposed label induces infringement of method-of-use patents.
• Whether the patent claims are valid and enforceable.
• Whether a polymer or dissolution limitation is met.
• Whether the ANDA applicant can launch at risk before final judgment.

A settlement agreement could establish a permitted launch date, a license, or restrictions on product labeling. Settlement terms can materially change the value of an excipient or generic-development program. Public FDA and court records should be reviewed together because Orange Book status does not reveal every commercial restriction created by a private settlement.

What commercial opportunities exist for LYRICA CR excipients?

Hypromellose supply

The highest-value opportunity is a qualified hypromellose platform for high-dose controlled-release tablets. Suppliers can pursue a dual strategy:

1. Sell the polymer as a compendial excipient for generic development.
2. Provide formulation-development support that improves dissolution matching and scale-up robustness.

Supplier qualification is difficult because a change in polymer grade can trigger comparative dissolution, stability, and regulatory documentation. Once qualified, the supplier may have a durable position in the customer’s manufacturing process.

Co-processed excipients

Co-processed cellulose, silicified materials, and dry-binding systems may improve flow and tablet strength. These products could reduce granulation steps or support direct compression. The opportunity is strongest if the formulation maintains release control without increasing tablet size.

Film-coating systems

A ready-to-use coating system can simplify production across the 82.5 mg, 165 mg, and 330 mg strengths. Commercial differentiation may come from faster coating cycles, improved color matching, lower defect rates, and reduced solvent or water consumption.

Generic finished products

A generic LYRICA CR program can target price-sensitive markets where once-daily dosing retains commercial value. The product’s opportunity is smaller than that of immediate-release pregabalin because the development program is more technically demanding and the reference product has a narrower strength architecture.

Reformulated delivery systems

A 505(b)(2) program could explore sprinkle formulations, smaller tablets, multiparticulates, or alternative controlled-release systems. These approaches face a high risk of clinical and regulatory differentiation requirements. They are more attractive where adherence, swallowing difficulty, or dosing convenience supports premium pricing.

How strong is the LYRICA CR patent estate?

The estate is strongest where claims combine pregabalin with a defined extended-release architecture, dissolution profile, dosing condition, or therapeutic method. It is weaker where protection depends only on commonly used excipients such as hypromellose, povidone, silica, or magnesium stearate.

Protection type	Relative barrier
Pregabalin compound patent	Low after expiration
Generic hydrophilic matrix concept	Low if broadly conventional
Specific CR formulation and dissolution limits	Moderate to high
Dose-specific tablet claims	Moderate
Method-of-use claims	Depends on label and claim scope
Manufacturing-process claims	Depends on process overlap and enforceability
Brand, trade dress, and product identification	Low for an ANDA product if labeling rules are followed

The strongest commercial moat is likely a combination of formulation know-how, validated manufacturing controls, patent claims, and regulatory history rather than any single excipient.

How does LYRICA CR compare with immediate-release pregabalin?

Immediate-release pregabalin has a broader generic manufacturing base, lower formulation complexity, and more established supplier alternatives. LYRICA CR has a narrower competitive field because the product requires controlled release and meal-related administration.

Factor	Immediate-release pregabalin	LYRICA CR
Formulation complexity	Lower	Higher
Excipient differentiation	Limited	Material
Generic competition	Broad	Narrower
Manufacturing risk	Lower	Higher
Dosing convenience	Lower	Higher
Bioequivalence sensitivity	Standard	Release- and food-effect sensitive
Licensing value	Commodity-oriented	Formulation and platform-oriented

What revenue exposure and launch scenarios exist?

Pfizer’s LYRICA franchise generated substantial revenue before generic erosion, but the relevant commercial exposure for LYRICA CR is smaller than the overall pregabalin franchise. The key revenue scenarios are:

• Controlled generic entry: Multiple ANDA approvals reduce price and share while preserving a market for once-daily therapy.
• Single challenger entry: A first approved generic may capture meaningful substitution before additional products arrive.
• Delayed entry: Patent litigation or settlement may preserve brand sales longer.
• Formulation-led competition: A differentiated 505(b)(2) product may avoid direct price competition but requires stronger clinical and commercial positioning.
• Excipient-platform licensing: Polymer or coating suppliers may earn recurring revenue from several generic applicants without selling a finished product.

For investors and licensors, the most valuable diligence points are current Orange Book listings, ANDA filing dates, Paragraph IV notices, any first-filer status, settlement restrictions, and whether generic approval includes all three reference strengths.

Key Takeaways

• LYRICA CR is a once-daily extended-release pregabalin tablet approved in 82.5 mg, 165 mg, and 330 mg strengths.
• Hypromellose is the core excipient opportunity because it controls matrix hydration and drug release.
• Povidone, colloidal silicon dioxide, magnesium stearate, talc, and coating materials support manufacturability and product robustness.
• Generic development requires more than matching the active ingredient; it requires control of dissolution, food effect, tablet mechanics, and dose strength.
• Original pregabalin compound protection is distinct from later extended-release formulation and method-of-use patents.
• The main commercial opportunities are qualified hypromellose supply, co-processed excipients, film-coating systems, generic finished products, and selected 505(b)(2) reformulations.
• Orange Book listings, Paragraph IV certifications, litigation, and settlement agreements determine the practical U.S. launch window.

FAQs

Can a generic manufacturer use a different hypromellose supplier for LYRICA CR?

Yes, but the alternative grade must produce comparable pharmaceutical performance. Supplier changes can affect dissolution, stability, scale-up, and regulatory comparability.

Is LYRICA CR interchangeable with generic immediate-release pregabalin?

No. The extended-release tablet has different dosing, release, pharmacokinetic, and food-use characteristics. Substitution depends on product-specific regulatory designation and prescribing instructions.

Which excipient has the greatest licensing potential for LYRICA CR-type products?

Hypromellose has the strongest platform potential because it directly controls extended release. Commercial value increases when the supplier provides formulation support, dissolution modeling, and regulatory documentation.

Could a multiparticulate pregabalin product compete with LYRICA CR?

It could pursue a differentiated regulatory pathway, but it would need to establish comparable or clinically justified exposure and address patents covering extended-release pregabalin methods or dosage forms.

What is the main manufacturing barrier for a LYRICA CR generic?

The central barrier is reproducible control of the release profile across strengths and manufacturing scales, particularly under fed conditions and after changes in polymer grade, compression, lubrication, or coating.

References

1. U.S. Food and Drug Administration. (2017). LYRICA CR (pregabalin) extended-release tablets: Prescribing information. Pfizer Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208211s000lbl.pdf

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.-b). ANDA submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-approval-process-anda-submissions

4. U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/